Hello, everybody, and welcome to Madrid. It’s a great delight to present the update on the Emerald-3 in regard to disease progression trajectory and post-progression outcomes. If you recall, we presented at ASCO the outcome of the Emerald-3, which looked into adding on chemoembolization to the stride regimen, or tremelimumab map, and also looked into the potential for lenvatinib...
Hello, everybody, and welcome to Madrid. It’s a great delight to present the update on the Emerald-3 in regard to disease progression trajectory and post-progression outcomes. If you recall, we presented at ASCO the outcome of the Emerald-3, which looked into adding on chemoembolization to the stride regimen, or tremelimumab map, and also looked into the potential for lenvatinib. And we came out with a clinically meaningful outcome, improving PFS and OS for the stride plus days, and we’re waiting for the matured data as well. In that study, the ALBI score and Child-Pugh scoring were looked into and looked for clinical measures. We also looked into the time to next therapy or next treatment, TTNT. And in this analysis today at ESMO, we were able to find out that liver function remained stable over the treatment period with the stride plus-minus lenvatinib plus days, with a consistent pattern of subsequent anti-cancer therapy use, irrespective of baseline liver function. So, nearly all did not matter, which is great. Number two is stride plus-minus lenvatinib, again, plus days, showed clinically meaningful improvement in post-progression outcomes in regard to time to next treatment, and PFS2 after the first PFS with favorable overall survival outcome versus sorafenib, regardless of the baseline ALBI scoring either. And still importantly, the safety outcomes were broadly consistent with the overall study population, regardless of the baseline ALBI grading. One more thing, we hope that we’ll see you soon again to connect you with the mature data for the Emerald 3 study. Thanks for listening.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.